Skip to main content

Table 3 Univariate analysis of prognostic factors in term of overall survival and HCC-specific overall survival

From: Clinical features and outcome of multiple primary malignancies involving hepatocellular carcinoma: A long-term follow-up study

Characteristic

HCC-specific overall survival rate (%)

Overall survival rate (%)

3y

5y

Pvalue

3y

5y

Pvalue

Gender

  

0.901

  

0.815

  Female (n = 7)

45.5

38.4

 

85.7

64.3

 

  Male (n = 61)

51.4

34.3

 

58.0

50.4

 

Age (years)*

  

0.441

  

0.612

  < 58 (n = 33)

52.3

47.1

 

62.7

62.7

 

  ≥58 (n = 35)

40.5

27.1

 

59.8

41.7

 

HBsAg status

  

0.148

  

0.909

  Negative (n = 23)

40.0

28.6

 

56.0

49.1

 

  Positive (n = 45)

50.8

36.2

 

62.4

51.8

 

AFP (ug/l)

  

0.034

  

0.252

  ≤ 25 (n = 30)

62.9

48.4

 

68.9

68.9

 

  >25 (n = 38)

32.6

27.2

 

54.9

39.6

 

GGT level (u/l)

  

0.040

  

0.073

  ≤ 50 (n = 23)

71.8

71.8

 

76.5

76.5

 

  > 50 (n = 45)

35.9

29.4

 

52.9

43.8

 

Cirrhosis

  

.255

  

0.078

  No (n = 17)

65.8

65.8

 

85.6

66.3

 

  Yes (n = 51)

40.9

29.5

 

52.9

46.8

 

Child-Pugh classification

  

0.334

  

0.083

  A (n = 49)

50.8

39.7

 

64.6

59.8

 

  B (n = 19)

36.4

27.3

 

48.2

32.8

 

Tumor size (cm)

  

0.865

  

0.537

  ≤5 (n = 28)

49.0

42.0

 

62.8

47.3

 

  >5 (n = 40)

44.6

31.5

 

59.7

48.0

 

Multiple tumors

  

0.001

  

0.221

  No (n = 49)

58.0

48.1

 

65.3

57.7

 

  Yes (n = 19)

11.1

11.1

 

62.1

41.4

 

Vascular invasion

  

0.001

  

0.977

  No (n = 58)

51.7

40.2

 

60.2

52.3

 

  Yes (n = 10)

0

0

 

66.8

53.4

 

TNM stage

  

<0.001

  

0.698

  I (n = 43)

58.4

50.0

 

61.4

54.0

 

  II/III (n = 25)

17.1

0

 

60.1

47.7

 

Time of appearance

  

0.360

  

0.008

  Synchronous (n = 22)

34.5

23.0

 

25.7

25.7

 

  Metachronous (n = 46)

50.3

40.3

 

72.8

61.3

 

Treatment for HCC

  

<0.001

  

0.160

  Resection (n = 35)

71.9

52.0

 

64.9

64.9

 

  Ablation (n = 8)

50.8

50.8

 

66.7

50.0

 

  TACE (n = 14)

0

0

 

50.0

37.6

 

  Supportive (n = 11)

0

0

 

40.0

26.7

 

Treatment for EHPM

  

0.067

  

<0.001

  Curative (n = 54)

47.3

33.2

 

72.4

63.4

 

  Palliative (n = 8)

19.2

19.2

 

35.7

17.9

 

  Supportive (n = 6)

11.7

11.7

 

0

0

 
  1. HCC: hepatocellular carcinoma, HBsAg: hepatitis B surface antigen, AFP: α-fetoprotein, GGT: gamma-glutamyltransferase, TACE: transarterial chemoembolization, EHPM: extrahepatic primary malignancy.
  2. * Patients were divided according to the median age.
  3. Resection vs. Ablation P = 0.346; Ablation vs. TACE P < 0.001; TACE vs. Supportive P = 0.413.
  4. Radical vs. Palliative P < 0.001; Palliative vs. Supportive P = 0.122.